Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B

References

• World Federation of HemophiliaWorld Federation of Hemophilia Report on the Annual Global Survey 2014Montreal, QCWorld Federation of Hemophilia2014
   Google Scholar
• FranchiniMFrattiniFCrestaniSSissaCBonfantiCTreatment of hemophilia B:focus on recombinant factor IXBiologics20137333823430394
   PubMedGoogle Scholar
• SrivastavaABrewerAKMauser-BunschotenEPTreatment Guidelines Working Group on Behalf of the World Federation of HemophiliaGuidelines for the management of hemophiliaHaemophilia2013191e1e4722776238
   PubMed Web of Science ®Google Scholar
• CDCUniversal Data Collection (UDC) SystemAtlanta, GAUS Centers for Disease Control and Prevention2011
   Google Scholar
• ElanderJBarryTAnalgesic use and pain coping among patients with haemophiliaHaemophilia20039220221312614373
   PubMed Web of Science ®Google Scholar
• MinersAHSabinCATolleyKHJenkinsonCKindPLeeCAAssessing health-related quality-of-life in individuals with haemophiliaHaemophilia19995637838510583523
   PubMed Web of Science ®Google Scholar
• MolhoPRollanNLebrunTEpidemiological survey of the orthopaedic status of severe haemophilia A and B patients in FranceHaemophilia200061233210632738
   PubMed Web of Science ®Google Scholar
• AznarJAMagallónMQuerolFGorinaETusellJMThe orthopaedic status of severe haemophiliacs in SpainHaemophilia20006317017610792475
   PubMed Web of Science ®Google Scholar
• LusherJMProphylaxis in children with hemophilia: is it the optimal treatment?Thromb Haemost19977817267299198246
   PubMed Web of Science ®Google Scholar
• AhlbergAHaemophilia in Sweden VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and BActa Orthop Scand Suppl196577Suppl3132
   Google Scholar
• HilgartnerMWHemophilic arthropathyAdv Pediatr1974211391654614656
   PubMedGoogle Scholar
• NilssonIMHednerUAhlbergAHemophilia prophylaxis in SwedenActa Paediatr Scand19766521291351258628
   PubMed Web of Science ®Google Scholar
• The National Hemophilia FoundationMedical and Scientific Advisory Council recommendations Concerning Prophylaxis [abstract]Medical Bulletin 193 Chapter Advisory No197New York, NYThe National Hemophilia Foundation1994
   Google Scholar
• BerntorpEAstermarkJBjorkmanSConsensus perspectives in prophylactic therapy for haemophilia: summary statementHaemophilia20039Suppl 114
   PubMed Web of Science ®Google Scholar
• LjiungRAranis-VournasSKurnik-AubergerKTreatment of children with haemophilia in Europe: a survey of 20 centres in 16 countriesHaemophilia20006661962411122385
   PubMed Web of Science ®Google Scholar
• BlanchetteVSManco-JohnsonMSantagostinoELjungROptimizing factor prophylaxis for the haemophilia population: where do we stand?Haemophilia200410Suppl 49710415479380
   PubMed Web of Science ®Google Scholar
• BissTTChanAKBlanchetteVSIwenofuLNMcLimontMCarcaoMDAssociation of Hemophilia Clinic Directors of Canada (AHCDC)Canadian Association of Nurses in Hemophilia Care (CANHC)The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis surveyHemophilia2008145923930
   PubMed Web of Science ®Google Scholar
• LjungRPetriniPTengbornLSjorinEHaemophilia B mutations in Sweden: apopulation-based study of mutational heterogeneityBr J Haematol20011131818611328285
   PubMed Web of Science ®Google Scholar
• NilssonIMBerntorpELofqvistTPetterssonHTwenty-five years’ experience of prophylactic treatment in severe haemophilia A and BJ Intern Med1992232125321640190
   PubMed Web of Science ®Google Scholar
• MorfiniMMannucciPMMarianiGEvaluation of prophylactic replacement therapy in haemophilia BScand J Haematol197616141471251139
   PubMedGoogle Scholar
• TagliaferriARivoltaGFRossettiGPattaciniCGandiniGFranchiniMExperience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacsThromb Haemost200696454254317003937
   PubMed Web of Science ®Google Scholar
• RothDAKesslerCMPasiKJRupBCourterSGTubridyKLRecombinant Factor IX Study GroupHuman recombinant factor IX: safety and efficacy studiesin hemophilia B patients previously treated with plasma-derived factor IX concentratesBlood200198133600366611739163
   PubMed Web of Science ®Google Scholar
• StobartKIorioAWuJKClotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or BCochrane Database Syst Rev20062CD003429
   Google Scholar
• WhiteGC2ndParachutes and prophylaxis: they both work!J Thromb Haemost2006461226122716706964
   PubMed Web of Science ®Google Scholar
• MannucciPMFranchiniMIs haemophilia B less severe than haemophilia A?Haemophilia201319449950223517072
   PubMed Web of Science ®Google Scholar
• WindygaJLinVWEpsteinJDImprovement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal StudyHaemophilia201420336236824251442
   PubMed Web of Science ®Google Scholar
• BerntorpEPharmacokinetics of plasma derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further studyHaemophilia201319680580724165154
   PubMed Web of Science ®Google Scholar
• EMACHMP guideline on the clinical investigation of recombinant and human plasma-derived factor IX products EMA/CHMP/BPWP/144552/2009London, UKEMA2011
   Google Scholar
• BerntorpEThe pharmacokinetics of clotting factor therapyHaemophilia20039435335912828668
   PubMed Web of Science ®Google Scholar
• LambertTRechtMValentinoLAReformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia BHaemophilia200713323324317498071
   PubMed Web of Science ®Google Scholar
• PowellJSPasiKJRagniMVPhase 3 study of recombinant factor IX Fc fusion protein in hemophilia BN Engl J Med2013369242313232324304002
   PubMed Web of Science ®Google Scholar
• BjorkmanSProphylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspectiveHaemophilia20039Suppl 110110812709045
   PubMed Web of Science ®Google Scholar
• UK NEQASU.K. National External Quality Assessment Scheme for Blood Coagulation: Report on Survey 207SheffieldUK NEQAS for Blood Coagulation2014 Available from: http://www.ukneqasbc.org/Documents/S207%20report%20v1.0(1).pdfAccessed October 11, 2016
   Google Scholar
• FengDStaffordKABrozeGJStaffordDWEvidence of clinically significant extravascular stores of factor IXJ Thromb Haemost201311122176217824112220
   PubMed Web of Science ®Google Scholar
• NazeefMSheehanJPNew developments in the management of moderate-to-severe hemophilia BJ Blood Med20167273827099538
   PubMed Web of Science ®Google Scholar
• SternDMKnitterGKisielWNawrothPPIn vivo evidence of intravascular binding sites for coagulation factor IXBr J Haematol19876622272323496917
   PubMed Web of Science ®Google Scholar
• GuiTRehemanANiHAbnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IVJ Thromb Haemost20097111843185119583826
   PubMed Web of Science ®Google Scholar
• GuiTLinHFJinDYCirculating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivoBlood2002100115315812070021
   PubMed Web of Science ®Google Scholar
• CheungWFvan den BornJKühnKKjellénLHudsonBGStaffordDWIdentification of the endothelial cell binding site for factor IXProc Natl Acad Sci U S A1996932011068110738855310
   PubMed Web of Science ®Google Scholar
• BjorkmanSPharmacokinetics of plasma derived and recombinant factor IX – implications for prophylaxis and on-demand therapyHaemophilia201319680881323786333
   PubMed Web of Science ®Google Scholar
• AhnstromJBerntorpELindvallKBjorkmanSA 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophiliaHaemophilia200410668969715569163
   PubMed Web of Science ®Google Scholar
• SantagostinoEMancusoMETripodiASevere hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profileJ Thromb Haemost20108473774320102490
   PubMed Web of Science ®Google Scholar
• BerntropEDolanGHermansCLaffanMSantagostinoETiedeAPharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?Haemophilia201420Suppl 7111
   Web of Science ®Google Scholar
• SchulmanSEeldeAHolmstromMStahlbergGOdebergJBlombackMValidation of a composite score for clinical severity of HemophiliaJ Thromb Haemost2008671113112118466317
   PubMed Web of Science ®Google Scholar
• VyasSEnocksonCHernandezLValentinoLATowards personalizing haemophilia care: using the Haemophilia Severity Score to assess 178 patients in a single institutionHaemophilia201420191423855877
   PubMed Web of Science ®Google Scholar
• PetterssonHAhlbergANilssonIMAradiologic classification of hemophilicarthropathyClin Orthop Relat Res1980149153159
   PubMed Web of Science ®Google Scholar
• Van DijkKFischerKvan der BomJGGrobbeeDEvan den BergHMVariability in clinical phenotype of severe haemophilia:the role of the first joint bleedHaemophilia200511543844316128885
   PubMed Web of Science ®Google Scholar
• UKHCDO annual report Available from: http://www.ukhcdo.org/wp-content/uploads/uploads/216/02/bleeding-disordre-statistics-for-April-2014-to-March-2015-v2-for-website.pdfAccessed July 18 2014
   Google Scholar
• KimHCMcMillanCWWhiteGCBergmanGEHortonMWSaidiPPurified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentratesBlood19927935685751531035
   PubMed Web of Science ®Google Scholar
• FurieBLimentaniSARosenfieldCGA practical guide to the evaluation and treatment of hemophiliaBlood1994841398018925
   PubMed Web of Science ®Google Scholar
• BrookerMRegistry of Clotting Factor Concentrates9th edReport No. 6Montreal, QCWorld Federation of hemophilia; 2012
   Google Scholar
• KimISChoiYWKangYSungHMSohnKWKimYSImprovement of virus safety of an antihemophilic factor IX by virus filtration processJ Microbiol Biotechnol20081871317132518667862
   PubMed Web of Science ®Google Scholar
• LudlamCATurnerMLManaging the risk of transmission of variant Creutzfeldt Jakob disease by blood productsBr J Haematol20061321132416371015
   PubMed Web of Science ®Google Scholar
• KeyNSNegrierCCoagulation factor concentrates: past, present, and futureLancet2007370958543944817679021
   PubMed Web of Science ®Google Scholar
• DietrichBSchivizAHoellrieglWPreclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia BInt J Hematol201398552553224061775
   PubMed Web of Science ®Google Scholar
• Di MinnoGCanaroMIronsideJWPathogen safety of long-term treatments for bleeding disorders: still relevant to current practiceHaematologica201398101495149824091928
   PubMed Web of Science ®Google Scholar
• BjorkmanSFolkessonABerntorpEIn vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical settingHaemophilia20071312817212717
   PubMed Web of Science ®Google Scholar
• EwensteinBMJoistJHShapiroADPharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia BTransfusion200242219019711896334
   PubMed Web of Science ®Google Scholar
• AlameluJBevanDSorensenBRangarajanSPharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover studyJ Thromb Haemost201412122044204825315324
   PubMed Web of Science ®Google Scholar
• WhiteGC2ndBeebeANielsenBRecombinant factor IXThromb Haemost19977812612659198163
   PubMed Web of Science ®Google Scholar
• PoonMCLillicrapDHensmanCCardRScullyMFRecombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance studyThromb Haemost200287343143511916075
   PubMed Web of Science ®Google Scholar
• KiskerCTEisbergASchwartzBMononine Study GroupProphylaxis in factor IX deficiency product and patient variationHaemophilia20039327928412694518
   PubMed Web of Science ®Google Scholar
• PoonMCPharmacokinetics of factors IX, recombinant activated factor VII and factor XIIIHaemophilia200612Suppl 4616916683998
   PubMed Web of Science ®Google Scholar
• ZakarijaAFactor IX replacement in surgery and prophylaxisBlood Coagul Fibrinolysis200415Suppl 2S5S715322450
   PubMedGoogle Scholar
• RoccaAPizzinelliSOliovecchioESantagostinoERocinoAIorioAItalian ad hoc study groupReplacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practicesin ItalyBlood Transfus201191606921084016
   PubMed Web of Science ®Google Scholar
• HackerMRGeraghtySManco-JohnsonMBarriers to compliance with prophylaxis therapy in haemophiliaHaemophilia20017439239611442644
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionSummary Report of UDC Activity NationalTreatment/Clinical Characteristics (Hemophilia) – Report of 31 December, 2011 Available from: https://www2a.cdc.gov/ncbddd/htcweb/UDC_Report/UDC_view1.asp?para1=NATION&para2=TREATH&para3=&ScreenWidth=1920&ScreenHeight=1080Accessed October 19, 2016
   Google Scholar
• GaterAThomsonTAStrandberg-LarsenMHaemophilia B: impact on patients and economic burden of diseaseThromb Haemost2011106339840421833450
   PubMed Web of Science ®Google Scholar
• De MoerloosePUrbancikWVan Den BergHMRichardsMA survey of adherence to haemophilia therapy in sixuropean countries: results and recommendationsHaemophilia200814593193818684125
   PubMed Web of Science ®Google Scholar
• MinersAHLeeCASetting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia AHaemophilia200410Suppl 15862
   PubMed Web of Science ®Google Scholar
• MinersARevisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia AHaemophilia200915488188719473422
   PubMed Web of Science ®Google Scholar
• Manco-JohnsonMJRiskeBKasperCKAdvances in care of children with hemophiliaSemin Thromb Hemost200329658559414719175
   PubMed Web of Science ®Google Scholar
• NathwaniACTuddenhamEGRangarajanSAdenovirus-associated virus vector-mediated gene transfer in hemophilia BN Engl J Med2011365252357236522149959
   PubMed Web of Science ®Google Scholar
• NathwaniACReissUMTuddenhamEGLong-term safety and efficacy of factor IX gene therapy in hemophilia BN Engl J Med2014371211994200425409372
   PubMed Web of Science ®Google Scholar
• ValentinoLARusenLElezovicISmithLMKorth-BradleyJMRendoPMulticentre, randomized, open-label study of ondemand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjectsHaemophilia201420339840624418368
   PubMed Web of Science ®Google Scholar
• KavakliKSmithLKuliczkowskiKOnce-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia BHaemophilia201622338138826823276
   PubMed Web of Science ®Google Scholar
• RendoPShaferFECharnigoRJCarrMOne-year assessment of coagulation markers and monitoring for thrombotic events in hemophilia B patients treated with nonacog alfa [abstract]Presented at: World Federation of Hemophilia World CongressJuly 8–12, 2012Paris, France
   Google Scholar